Unveiling the enigmatic role of MYH9 in tumor biology: a comprehensive review.

IF 8.2 2区生物学 Q1 CELL BIOLOGY

Cell Communication and Signaling Pub Date : 2024-08-27 DOI:10.1186/s12964-024-01781-w

Yunkuo Li, Yujie Pan, Xiangzhe Yang, Yuxiong Wang, Bin Liu, Yanghe Zhang, Xin Gao, Yishu Wang, Honglan Zhou, Faping Li

{"title":"Unveiling the enigmatic role of MYH9 in tumor biology: a comprehensive review.","authors":"Yunkuo Li, Yujie Pan, Xiangzhe Yang, Yuxiong Wang, Bin Liu, Yanghe Zhang, Xin Gao, Yishu Wang, Honglan Zhou, Faping Li","doi":"10.1186/s12964-024-01781-w","DOIUrl":null,"url":null,"abstract":"<p><p>Non-muscle myosin heavy chain IIA (MYH9), a member of the non-muscle myosin II (NM II) family, is widely expressed in cells. The interaction of MYH9 with actin in the cytoplasm can hydrolyze ATP, completing the conversion of chemical energy to mechanical motion. MYH9 participates in various cellular processes, such as cell adhesion, migration, movement, and even signal transduction. Mutations in MYH9 are often associated with autosomal dominant platelet disorders and kidney diseases. Over the past decade, tumor-related research has gradually revealed a close relationship between MYH9 and the occurrence and development of tumors. This article provides a review of the research progress on the role of MYH9 in cancer regulation. We also discussed the anti-cancer effects of MYH9 under special circumstances, as well as its regulation of T cell function. In addition, given the importance of MYH9 as a key hub in oncogenic signal transduction, we summarize the current therapeutic strategies targeting MYH9 as well as the ongoing challenges.</p>","PeriodicalId":55268,"journal":{"name":"Cell Communication and Signaling","volume":null,"pages":null},"PeriodicalIF":8.2000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11351104/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Communication and Signaling","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1186/s12964-024-01781-w","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Non-muscle myosin heavy chain IIA (MYH9), a member of the non-muscle myosin II (NM II) family, is widely expressed in cells. The interaction of MYH9 with actin in the cytoplasm can hydrolyze ATP, completing the conversion of chemical energy to mechanical motion. MYH9 participates in various cellular processes, such as cell adhesion, migration, movement, and even signal transduction. Mutations in MYH9 are often associated with autosomal dominant platelet disorders and kidney diseases. Over the past decade, tumor-related research has gradually revealed a close relationship between MYH9 and the occurrence and development of tumors. This article provides a review of the research progress on the role of MYH9 in cancer regulation. We also discussed the anti-cancer effects of MYH9 under special circumstances, as well as its regulation of T cell function. In addition, given the importance of MYH9 as a key hub in oncogenic signal transduction, we summarize the current therapeutic strategies targeting MYH9 as well as the ongoing challenges.

查看原文本刊更多论文

揭示 MYH9 在肿瘤生物学中的神秘作用：全面综述。

非肌肉肌球蛋白重链 IIA（MYH9）是非肌肉肌球蛋白 II（NM II）家族的成员，在细胞中广泛表达。MYH9 与细胞质中的肌动蛋白相互作用，可以水解 ATP，完成化学能到机械运动的转化。MYH9 参与各种细胞过程，如细胞粘附、迁移、运动甚至信号转导。MYH9 基因突变通常与常染色体显性血小板疾病和肾脏疾病有关。近十年来，肿瘤相关研究逐渐揭示了 MYH9 与肿瘤发生和发展之间的密切关系。本文综述了 MYH9 在癌症调控中作用的研究进展。我们还讨论了 MYH9 在特殊情况下的抗癌作用，以及它对 T 细胞功能的调控。此外，鉴于 MYH9 作为致癌信号转导关键枢纽的重要性，我们总结了目前针对 MYH9 的治疗策略以及当前面临的挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cell Communication and Signaling CELL BIOLOGY-

CiteScore

11.00

自引率

0.00%

发文量

180

期刊介绍： Cell Communication and Signaling (CCS) is a peer-reviewed, open-access scientific journal that focuses on cellular signaling pathways in both normal and pathological conditions. It publishes original research, reviews, and commentaries, welcoming studies that utilize molecular, morphological, biochemical, structural, and cell biology approaches. CCS also encourages interdisciplinary work and innovative models, including in silico, in vitro, and in vivo approaches, to facilitate investigations of cell signaling pathways, networks, and behavior. Starting from January 2019, CCS is proud to announce its affiliation with the International Cell Death Society. The journal now encourages submissions covering all aspects of cell death, including apoptotic and non-apoptotic mechanisms, cell death in model systems, autophagy, clearance of dying cells, and the immunological and pathological consequences of dying cells in the tissue microenvironment.